Chemotherapy in malignant mesothelioma: What's up, doc?

Journal of Thoracic Oncology

Volumn 1, Issue 4, 2006, Pages 279-280

  Van Meerbeeck, Jan P ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PEMETREXED; RALTITREXED; VINDESINE; ANTINEOPLASTIC AGENT; FOLIC ACID ANTAGONIST;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FOLIC ACID ANTAGONISTS; HUMANS; MESOTHELIOMA; RANDOMIZED CONTROLLED TRIALS;

EID: 34247203168     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200605000-00001     Document Type: Editorial

References (15)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
2. Van Meerbeeck J, Gaafar R, Manegold C, et al. A Randomized Phase III Study of Cisplatin with or without Raltitrexed in Patients with Malignant Pleural Mesothelioma: an Intergroup Study of the EORTC Lung Cancer Group and the NCIC. J Clin Oncol. 2005;23:6881-6889.
3. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol. 2006;17:270-275.
4. Baas P, Ardizzoni A, Grossi F. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer. 2003;39:353-357.
5. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamine B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556-1561.
6. Van den Bogaert DPM, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thor Oncol. 2006;1:25-30.
7. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of Raltitrexed and Oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. Journal of Clinical Oncology. 2003;2:349-354.
8. Soto Parra H, Zucali P, Favaretto A, et al. A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2006;49 (2):S229.
9. Janne P, Simon G, Langer C, et al. An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma: A phase II clinical trial. Lung Cancer. 2006;49 (2):S281.
10. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep. 2003;5:114-125.
11. Pivot X, Wadler S, Kelly C, et al. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Ann Oncol. 2001;12:1595-1599.
12. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant Chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451-3457.
13. Krug L, Pass H, Rusch V, et al. A multicenter phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM). Lung Cancer. 2006;49 (2):S223.
14. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and postoperative high dose radiotherapy for locally advanced malignant pleural mesothelioma (MPM): a phase II trial. J Thor Oncol. 2006;1:289-295.
15. National Cancer Research Networks (NCRN). Trials portfolio: mesothelioma trials: http://www.ncrn.org.uk/portfolio/summary.asp (accessed February 25, 2006).